Navigation Links
Penn researchers use honeybee venom toxin to develop a new tool for studying hypertension
Date:9/17/2008

PHILADELPHIA - Researchers at the University of Pennsylvania School of Medicine have modified a honeybee venom toxin so that it can be used as a tool to study the inner workings of ion channels that control heart rate and the recycling of salt in kidneys. In general, ion channels selectively allow the passage of small ions such as sodium, potassium, or calcium into and out of the cell.

The study, published in the Proceedings of the National Academy of Sciences, is from the laboratory of Zhe Lu, M.D, Ph.D., Professor of Physiology and a Howard Hughes Medical Institute Investigator, who looked at the action of a natural bee toxin on inward-rectifier potassium channels, Kir channels for short, to identify new approaches to treat cardiovascular disease.

The honeybee venom toxin, called tertiapin, or TPN, stops the flow of potassium ions across cell membranes by plugging up the opening of Kir channels on the outside of cells. Kir channels in kidneys are potential new targets for treating hypertension. "The clue comes from patients with genetic defects in these channels who lose a lot of sodium because it cannot be effectively reabsorbed and thus have low blood pressure," notes Lu. "An inhibitor specifically against these kidney channels will allow this idea to be tested."

Developing a specific inhibitor for one type of Kir channel has been challenging because the target site is very similar among different types of Kir channels. For example, while TPN inhibits Kir type 1 channels in kidney cells, it also inhibits other types of Kir channels in heart cells. After more than a decade, Lu and his colleagues succeeded in bioengineering a TPN that selectively inhibits Kir channels important for salt recycling in kidneys.

By introducing two mutations into TPN, they engineered a variant, called TPNLQ, which stems the flow of potassium ions in renal Kir type 1 channels at low concentrations, and with a 250-fold sensitivity over
'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Johns Hopkins researchers suppress hunger hormone
2. Penn researchers identify natural tumor suppressor
3. Two U.S. Researchers Win Prestigious International Science Award
4. Researchers receive grant to study ways of preventing heart disease
5. Yerkes researchers create animal model of chronic stress
6. Surgical technique halts cell loss, Parkinsons researchers find
7. Millions face undiagnosed heart risk say researchers after mass screening
8. Superbug breast infections controllable in nursing mothers, UT Southwestern researchers find
9. Heart attack patients who stop statin risk death, say McGill researchers
10. UTMB researchers test new vaccine to fight multiple influenza strains
11. New method to overcome multiple drug resistant diseases developed by Stanford researchers

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...ers who use medical load cells at the heart of the...ging in technology partner Flintec early in the de...ical manufacturers are calling in Flintec load cel...ensuring that progress will not be constrained by ...technology. , (PRWEB) Nov...
(Date:11/26/2009)...te (TM) has been shown in studies to be effective ...ed by an overload of copper, and certain metastati...r, is known about how the drug works at the molecu...versity researchers now has provided an invaluable... to copper-loaded metallochaperones. The drug sequ...
(Date:11/26/2009)...tal (RTDental), a leading dental group practice in...sion of its services to include LUMINEERS by a cer... Durham, NC (PRWEB) -- Res...Dr. Doug Macmillan, an experienced LUMINEERS Den...aining seminar. RTDental’s ability to fulfi...
(Date:11/25/2009)...wswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. ...will host two investor events in December: ,, ....m. CT/10:00 a.m. ET ,, Principal investigato...filzomib in relapsed and/or refractory multiple my... Hematology (ASH) Annual Meeting and Exposition in...
(Date:11/25/2009)...USNewswire/ -- The Black AIDS Institute recently h...tive leadership for 2010. ,, The new Board Memb...cialties in public policy, law, finance, governmen...eneurship. The Board also comes from a wide range ...l and gay Black men and women, some living with HI...
Breaking Medicine News(10 mins):Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2
...ALE, N.Y., May 11 Misonix, Inc. (Nasdaq: MSON )...ical device technology, which in Europe is used fo...cute health conditions, today reported financial r...r VP and Chief Financial Officer, will host a conf...
...TON, May 11, 2009 News media registration for one...eetings is now open. The 238th National Meeting & ...will be held Aug. 16-20, 2009, in Washington, D.C....ude more than 8,400 reports on new discoveries abo...
...ality videoconferencing can increase patient acces...her underserved areas; and a transient ischemic at...roke, should be treated with the same urgency as a...ssociation . , Telemedicine Statement Highlights...
...er Hair Removal System Called a "Medical Must Have...e leader in at-home aesthetic devices, was feature... popular national daytime show that offers viewers...emoval System was included in a segment that showc...
...N, N.J., May 11 Derma Sciences, Inc. (OTC Bul...are products, announced plans to release its first... 18, 2009. The Company will hold a conference cal...asscode 98098954 to access the call. You may also ...
...te-stage cancer greater in city dwellers than in r...y 11 (HealthDay News) -- Living in the city could ...much later stages of their development, new resear...ncer later in the disease,s progression than their...
Other Medicine News:Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 2Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 3Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 4Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 5Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 6Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 7Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 8Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 9Health News:Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009 10Health News:Videoconferencing can increase patient access to stroke specialists 2Health News:Videoconferencing can increase patient access to stroke specialists 3Health News:TRIA Laser Hair Removal System Debuts on 'The Doctors' 2Health News:Derma Sciences Announces Date of Its First Quarter 2009 Earnings Release and Conference Call 2Health News:Where You Live May Affect Your Cancer Diagnosis 2
(Date:11/25/2009)...RNewswire-FirstCall/ -- Abaxis, Inc. (Nasdaq: ABA...t-of-care blood analysis systems, announced today ...officer, will present at the 21st Annual Piper Jaf... 2, 2009 at 2:00 p.m. ET. The conference will be h... ,, About Abaxis ,, Abaxis develops, manu...
(Date:11/25/2009)...RNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: N...ing products for minimally disruptive surgical tre...l host a conference call on Monday, November 30, 2...ce call will focus on current issues relative to r...nclude comments from management followed by a shor...
(Date:11/25/2009)...tlinker.comannouncesthatanewmarketresearchreportis...very-USMarketTrends&Analysis http://www.repor...-Market-Trends--Analysis.html ,, TheUSintranas...peuticapplicationsfromthedeliveryofconventionalloc...icdrugs.Thefutureofthetechnologyhingesontotheeffec...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3NuVasive Announces Conference Call and Webcast Regarding Reimbursement 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5University of Louisville neuroscientists hope to get people walking again 58667 1Frozen assets 3A NIAID researchers turn to unique resource for clues to norovirus evolution 10218 1Frozen assets 3A NIAID researchers turn to unique resource for clues to norovirus evolution 10218 2Frozen assets 3A NIAID researchers turn to unique resource for clues to norovirus evolution 10218 3Experts gather at McGill University to address food security challenges 10216 1
...m, January 19 , - New Funds to Drive Clinical...l-Based Therapy for Heart Failure , Cardio3 Bi... specialising,in cell-based therapies for the trea...2 million in a successful Series B fund raising ro...f new and existing investors, will be,used to fina...
...rin Co., Ltd. (Chiyoda-ku, Tokyo Japan; President,...o Time) that it has decided to continue the domest... disease drug KW-6002 (generic name: Istradefyllin...al in Japan. , , KW-6002 has a novel mechanism of...e A2A receptor. Kyowa Hakko Kirin initiated the cl...
Other Medicine Technology:Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding 2Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding 3Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding 4Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding 5Kyowa Hakko Kirin Announces Development Policy for Anti-Parkinson's Disease Drug KW-6002 (Istradefylline) 2
... LD400 FT is an affordable full-field, autoperimet...g exam time by at least 40%. It has a small footpr...rapid setup and easy two-button operation making i...endly. The LD 400 FT is the workhorse of the Parad...
...Clear Corneal Diamond Knife is a unique design dev...anta Maria, California. This special knife was cre...rument that could be used in performing his Clear ...ollaboration between KOI and Dr. Shepard, this kni...
...g ClosureWire Vascular Closure System (VCS) utiliz...c Compression., ,The Boomerang ClosureWire tec... the inside of the arteriotomy and just outside th...ompression of both the arteriotomy and tract. The ...
EndoProbe Handpieces
Medicine Products: